American Society of Hematology

SHERPA: Blue

People

  1. Giralt
    Giralt
  2. Zelenetz
    Zelenetz
  3. Levine
    Levine
  4. Perales
    Perales
  5. Tallman
    Tallman
  6. O'Reilly
    O'Reilly
  7. Horwitz
    Horwitz
  8. Devlin
    Devlin
  9. Palomba
    Palomba
  10. Abdel-Wahab
    Abdel-Wahab

Groups

  1. Department of Medicine (4000)
  2. Hematologic Malignancies, Division of (3803)
  3. Center for Hematologic Malignancies (3680)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1343)
  6. Sloan Kettering Institute Faculty (1075)
  7. Bone Marrow Transplant (988)
  8. Center for Molecular Imaging and Biotechnology (CMIB) (955)
  9. Lymphoma (941)
  10. Tow Center for Developmental Oncology (TCDO) (882)
Search Within
Formats
  1. Meeting Abstract (4150)
  2. Journal Article (1257)
  3. Research Letter (46)
  4. Review (44)
  5. Editorial (35)
  6. Guidelines (13)
  7. Correspondence (7)
  8. Miscellaneous (3)
Groups
  1. Department of Medicine (4000)
  2. Hematologic Malignancies, Division of (3803)
  3. Center for Hematologic Malignancies (3680)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1343)
  6. Sloan Kettering Institute Faculty (1075)

More Groups

People
  1. Sergio Giralt (348)
  2. Andrew Zelenetz (341)
  3. Ross Levine (316)
  4. Miguel-Angel Perales (312)
  5. Martin Tallman (301)
  6. Richard O'Reilly (281)

More People

Years
  1. 2025 (64)
  2. 2024 (428)
  3. 2023 (478)
  4. 2022 (369)
  5. 2021 (284)
  6. 2020 (261)

More Years

Publications
  1. Blood (5174)
  2. Blood Advances (331)
  3. Hematology-American Society of Hematology Education Program (50)

Results (5555)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Efficacy of brentuximab vedotin maintenance therapy following autologous stem cell transplantation in patients with relapsed/refractory classical Hodgkin lymphoma with and without pre-transplant exposure to novel agents
    Meeting Abstract

    Falade, A. S.; Redd, R. A.; Shah, H.; Baron, K.; Iyengar, S.; Desai, S. H.; Ansell, S. M.; Micallef, I.; Nedved, A.; Ganesan, N.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Contemporary multiple myeloma treatment patterns among HCPs and concordance with expert recommendations: Analysis of an interactive online decision support tool
    Meeting Abstract

    Brandt, K. G.; Rosenthal, K.; Kumar, S. K.; Lentzsch, S.; Lonial, S.; Usmani, S. Z.; Quill, T. A.; Mikhael, J. R.
    Blood (2023)

    Fulltext@MSK | Save
  • Manufacturing, characterization and anti-tumor activity of allogeneic CD19-CAR cytokine-induced killer (CIK) cells engineered with non-viral sleeping beauty transposon system and armored with IL-18
    Meeting Abstract

    Contreras-Ruiz, L.; Pace, B.; Kohnke, D. E.; Viruet, L.; Adams, M.; Krisko, J. F.; Leesnitzer, N.; Velie, M.; Tettamanti, S.; Pisani, I.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Real-world patient profile and step-up dosing process of early initiators of teclistamab for multiple myeloma in US hospitals - An updated analysis using premier healthcare database
    Meeting Abstract

    Tan, C. R.; Kim, N.; Chinaeke, E.; Hester, L.; Fowler, J.; Gifkins, D.; Lin, D.; Walker, S.; Fu, A. Z.; Wu, B.
    Blood (2023)

    Fulltext@MSK | Save
  • Multicenter retrospective evaluation of treatment of high-risk acute promyelocytic leukemia (APL): Results from the Hematology Research Outcomes (HERO) Consortium
    Meeting Abstract

    Benitez, L.; Marx, K. R.; Buhlinger, K. M.; Clark, S. M.; Reid, J. H.; Rausch, C. R.; Gatwood, K. S.; Stump, S. E.; Shah, R.; Ciervo, J.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Efficacy and safety of elranatamab in Black patients with relapsed/refractory multiple myeloma (RRMM): A Subgroup analysis of the magnetismm studies
    Meeting Abstract

    Varshavsky-Yanovsky, A.; Jethava, Y.; Stevens, D. A.; Nooka, A. K.; Stiff, P. J.; Perez-Cruz, I.; Leip, E.; Lesokhin, A.
    Blood (2023)

    Fulltext@MSK | Save
  • ASC2ESCALATE: A US phase 2, open-label, single-arm, dose-escalation study of asciminib (ASC) monotherapy in patients (Pts) with chronic myeloid leukemia in chronic phase (CML-CP) as second-line (2L) and first-line (1L) treatment
    Meeting Abstract

    Atallah, E. L.; Mauro, M.; Sasaki, K.; Levy, M.; Koller, P. B.; Yang, D.; Laine, D.; Sabo, J.; Gu, E.; Cortes, J.
    Blood (2023)

    Fulltext@MSK | Save
  • Revumenib maintenance therapy following revumenib-induced remission and transplant
    Meeting Abstract

    Zucenka, A.; Issa, G. C.; Arellano, M.; Khazal, S.; Khera, N.; Stock, W.; Cuglievan, B.; Gu, Y.; Nguyen, H. V.; Smith, A. R.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Outcomes of sequential CD19-directed therapies in relapsed and refractory large B cell lymphoma
    Meeting Abstract

    Qualls, D. A.; Lambert, N.; Caimi, P. F.; Merrill, M. H.; Pullarkat, P.; Godby, R. C.; Bond, D. A.; Wehmeyer, G.; Romancik, J. T.; Amoozgar, B.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Interaction between presenting features, co-occurring mutations, MRD and induction treatment influences outcome in adults with NPM1 mutated AML - An analysis of 1357 patients in the UK NCRI AML17 and AML19 studies
    Meeting Abstract

    Othman, J.; Potter, N.; Ivey, A.; Tazi, Y.; Papaemmanuil, E.; Jovanovic, J.; Freeman, S. D.; Gilkes, A.; Thomas, I.; Johnson, S.; more...
    Blood (2023)

    Fulltext@MSK | Save